ASH41020 / Ashvattha Therap - LARVOL DELTA

Ashvattha Therapeutics Presents Promising Preclinical Data on New Dendranib Nanomedicine Candidate ASH41020 at the 16th International Society of Neuroimmunology Congress (ISNI) (GlobeNewswire) - "Ashvattha Therapeutics...today presented preclinical data showcasing anti-inflammatory and immunomodulatory effects of ASH41020....The preclinical data were presented in a poster at the 16th International Society of Neuroimmunology Congress (ISNI) held at the Centre des Congrès Québec in Québec City, Canada, from August 21st – 24th, 2023, and accessible here....In differentiated human primary monocytes, ASH41020 decreased M1 and increased M2 macrophage proportion in a dose dependent manner in the M1 polarizing environment. In the M2 polarizing environment, ASH41020 treatment did not affect M1 macrophage proportion but increased M2 macrophage proportion. In the EAE model of MS, treatment with ASH41020 after disease onset decreased symptom severity in a dose dependent manner. The magnitude of this effect was similar to fingolimod, a medication used to treat MS."

Preclinical • CNS Disorders • Immunology • Multiple Sclerosis